Key facts
- Notable investors include University of Utah.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Otter Immuno-oncology
- ·The full record, as it builds
Funding rounds
No funding rounds for Otter Immuno-oncology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Otter Immuno-oncology
Operator of a seed-stage, preclinical, immunology-focused biopharmaceutical company based in Maryland, United States. The company is currently operating in stealth mode.
- Sector
- Healthcare
- HQ
- MD
- Founded
- 2023
- Website
- otter-io.com/
- Ownership
- Privately Held (backing)
Otter Immuno-oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Otter Immuno-oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Otter Immuno-oncology in its N-PORT filings yet. We sweep new filings monthly.